A model-based PK/PD antimicrobial chemotherapy drug development platform to simultaneously combat infectious diseases and drug resistance

AAPS Advances in the Pharmaceutical Sciences Series

Volumn 2011, Issue 1, 2011, Pages 251-279

  Jumbe, N L'ntshotsholé ^a   Drusano, George L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; AMPICILLIN; ANTIBIOTIC AGENT; LEVOFLOXACIN; RIFAMYCIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BIOLOGICAL WARFARE; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COMBINATION; DRUG INTERACTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; GENE TRANSFER; HUMAN; IN VITRO STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERIAL LOAD; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; ENTEROBACTER CLOACAE; HORIZONTAL GENE TRANSFER; HOSPITAL ACQUIRED PNEUMONIA; HOST RESISTANCE; IC 50; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONTE CARLO METHOD; PHARMACODYNAMICS; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PNEUMOCOCCAL INFECTION; RESPIRATORY TRACT INFECTION; SIMULATION; TISSUE DISTRIBUTION;

EID: 84875731883     PISSN: 22107371     EISSN: 2210738X     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7415-0_12     Document Type: Article

References (125)

1. Allen MC, Shah TS, Day WW (1998) Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and application. Pharm Res 15(1):93-97
2. Alonso A, Campanario E, Martinez JL (1999) Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa. Microbiology 145(Pt 10):2857-2862
3. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44(1):79-86
4. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF (2001) Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with communityacquired respiratory tract infections. Antimicrob Agents Chemother 45(10):2793-2797
5. Andes DR, Craig WA (1999) Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 13(3):595-618
6. Andes D, Stamsted T, Conklin R (2001) Pharmacodynamics of amphotericin B in a neutropenicmouse disseminated-candidiasis model. Antimicrob Agents Chemother 45(3):922-926
7. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GK, Zelenitsky SA (2005) Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 39(1):32-38
8. Barclay ML, Begg EJ (2001) Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 61(6):713-721
9. Beaber JW, Hochhut B, Waldor MK (2004) SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 427(6969):72-74
10. Bermejo Martin JF, Jimenez JL, Munoz-Fernandez A (2003) Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered. Med Sci Monit 9(6):SR29-SR34
11. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89-95
12. Black JW, Leff P, Shankley NP (1985) An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 84(2):561-571
13. Blaser J, Stone BB, Zinner SH (1985) Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother 27(3):343-349
14. Boik JC, Newman RA, Boik RJ (2008) Quantifying synergism/antagonism using nonlinear mixedeffects modeling: a simulation study. Stat Med 27(7):1040-1061
15. Boshoff HI, Reed MB, Barry CE III, Mizrahi V (2003) DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113(2):183-193
16. Boucher AN, Tam VH (2006) Mathematical formulation of additivity for antimicrobial agents. Diagn Microbiol Infect Dis 55(4):319-325
17. Bradley JS, Dudley MN, Drusano GL (2003) Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J 22(11):982-992; quiz 993-985
18. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA (2002) Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2:35
19. Cappelletty DM, Rybak MJ (1996) Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 40(3):677-683
20. Centers for Disease Control and Prevention (2006) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs -worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 55(11):301-305
21. Chambers HF, Kennedy S (1990) Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 34(4):510-514
22. Chen YH, Peng CF, Lu PL, Tsai JJ, Chen TP (2004) In vitro activities of antibiotic combinations against clinical isolates of Pseudomonas aeruginosa. Kaohsiung J Med Sci 20(6):261-267
23. Chopra I, Roberts M (2001) Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-260
24. Chung P, McNamara PJ, Campion JJ, Evans ME (2006) Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother 50(9):2957-2965
25. Cirz RT, Chin JK, Andes DR, de Crecy-Lagard V, Craig WA, Romesberg FE (2005) Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol 3(6):e176
26. Cirz RT, Romesberg FE (2006) Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob Agents Chemother 50(1):220-225
27. Coates A, Hu Y, Bax R, Page C (2002) The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 1(11):895-910
28. Colburn WA (2000) Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J Clin Pharmacol 40(12 Pt 2):1419-1427
29. Craig WA (1998a) Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J 77(6 Suppl):7-11; discussion 11-12
30. Craig WA (1998b) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1-10; quiz 11-12
31. Craig WA, Ebert SC (1990) Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 74:63-70
32. Craig WA, Redington J, Ebert SC (1991) Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27(Suppl):S29-S40
33. Dagan R (2003) Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. Int J Infect Dis 7(Suppl 1):S21-S26
34. Dalla Costa T, Derendorf H (1996) AUIC -a general target for the optimization of dosing regimens of antibiotics? Ann Pharmacother 30(9):1024-1028
35. Dalla Costa T, Nolting A, Rand K, Derendorf H (1997) Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 35(10):426-433
36. Davies J (1994) Inactivation of antibiotics and the dissemination of resistance genes. Science 264:375-382
37. Davis BD, Maas WK (1952) Analysis of the biochemical mechanism of drug resistance in certain bacterial mutants. Proc Natl Acad Sci USA 38(9):775-785
38. Dean CR, Visalli MA, Projan SJ, Sum PE, Bradford PA (2003) Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47:972-978
39. Deshpande D, Srivastava S, Meek C, Leff R, Hall GS, Gumbo T (2010) Moxifloxacin pharmacokinetics/ pharmacodynamics and optimal dose and susceptibility breakpoint identification for the treatment of disseminated Mycobacterium avium infection. Antimicrob Agents Chemother 54:2534-2539
40. Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61(3):377-392
41. Drusano GL (1990) Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scand J Infect Dis Suppl 74:235-248
42. Drusano GL (1998a) Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J Infect Dis 178:360-367
43. Drusano GL (1998b) Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis 27(Suppl1): S111-S116
44. Drusano GL (2001) Use of preclinical data for the choice of a Phase II/III dose for evernimicin with application to decision support for identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45:13-22
45. Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat Rev Microbiol 2(4):289-300
46. Drusano GL, Johnson DE, Rosen M, Standiford HC (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37(3):483-490
47. Drusano GL, Prichard M, Bilello PA, Bilello JA (1996) Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: guidance in regimen choice for clinical trial evaluation. Antimicrob Agents Chemother 40(5):1143-1147
48. Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, LaFon S, Rogers M, Prince W, Bye A, Bilello JA (2000) Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob Agents Chemother 44(6):1655-1659
49. Drusano GL, Moore KHP, Kleim JP, Prince W, Bye A (2002) Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through the use of population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 46:913-916
50. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J (2004) Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 189(9):1590-1597
51. Drusano GL, Louie A, Deziel M, Gumbo T (2006) The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. Clin Infect Dis 42(4):525-532
52. Drusano GL, Liu W, Brown DL, Rice LB, Louie A (2009) Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis 199(2):219-226
53. Dudley MN, Ambrose PG. Monte Carlo PK-PD Simulation and New Cefotaxime (CTX), Ceftriaxone (CRO), and Cefepime (FEP) Susceptibility Breakpoints for S. pneumoniae, including Strains with Reduced Susceptibility to Penicillin. Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. A-635. Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd: 2002: San Diego, Calif.)
54. Eagle H (1948) The paradoxically retarded bactericidal activity of penicillin at high concentrations in vitro and in vivo. J Clin Invest 27(4):531
55. Eagle H (1949) The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and Treponema pallidum. J Exp Med 90(6):595-607
56. Eagle H (1952) Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 13(4):389-399
57. Eagle H (1954) The multiple mechanisms of penicillin resistance. J Bacteriol 68(5):610-616
58. Eagle H (1955) The mechanism of action of penicillin. J Lancet 75(1):1-6
59. Eagle H, Fleischman R, Levy M (1953a) Continuous vs. discontinuous therapy with penicillin; the effect of the interval between injections on therapeutic efficacy. N Engl J Med 248(12):481-488
60. Eagle H, Fleischman R, Levy M (1953b) On the duration of penicillin action in relation to its concentration in the serum. J Lab Clin Med 41(1):122-132
61. Ernst EJ, Klepser ME, Petzold CR, Doern GV (2002) Evaluation of survival and pharmacodynamic relationships for five fluoroquinolones in a neutropenic murine model of pneumococcal lung infection. Pharmacotherapy 22(4):463-470
62. Fidler M, Kern SE (2006) Flexible interaction model for complex interactions of multiple anesthetics. Anesthesiology 105(2):286-296
63. Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH (1998) Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 42(3):659-665
64. Firsov AA, Vasilov RG, Vostrov SN, Kononenko OV, Lubenko IY, Zinner SH (1999) Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in vitro dynamic model. J Antimicrob Chemother 43(4):483-490
65. Fish DN, Piscitelli SC, Danziger LH (1995) Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15(3):279-291
66. Frimodt-Moller N (2002) How predictive is PK/PD for antibacterial agents? Int J Antimicrob Agents 19(4):333-339
67. Giamarellou H (1986) Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 80(6B):126-137
68. Gniadkowski M (2008) Evolution of extended-spectrum beta-lactamases by mutation. Clin Microbiol Infect 14(Suppl 1):11-32
69. Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P (2008) The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol 22(6):633-648
70. Greco WR, Park HS, Rustum YM (1990) Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-Darabinofuranosylcytosine. Cancer Res 50(17):5318-5327
71. Gross M, Burli R, Jones P, Garcia M, Batiste B, Kaizerman J, Moser H, Jiang V, Hoch U, Duan JX, Tanaka R, Johnson KW (2003) Pharmacology of novel heteroaromatic polycycle antibacterials. Antimicrob Agents Chemother 47(11):3448-3457
72. Guerillot F, Carret G, Flandrois JP (1993) Mathematical model for comparison of time-killing curves. Antimicrob Agents Chemother 37(8):1685-1689
73. Gumbo T, Louie A, Deziel MR, Drusano GL (2005) Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrob Agents Chemother 49(8):3178-3181
74. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL (2007) Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51(11):3781-3788
75. Hawser SP (2006) Antibacterial drug discovery and development [mdash] SRI's 11th annual summit. IDrugs 9:390-393
76. Hirata T, Saito A, Nishino K, Tamura N, Yamaguchi A (2004) Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 48:2179-2184
77. Hollenstein U, Brunner M, Mayer BX, Delacher S, Erovic B, Eichler HG, Muller M (2000) Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin Pharmacol Ther 67(3):229-236
78. Hooper DC (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 31(Suppl 2):S24-S28
79. Hopwood DA (1985) Production of "hybrid" antibiotics by genetic engineering. Nature 314:642-644
80. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/ pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28(2):143-160
81. Jacobs MR (2003) How can we predict bacterial eradication? Int J Infect Dis 7(Suppl 1):S13-S20
82. Jacobs MR (2004) Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae. Clin Microbiol Infect 10(Suppl 2):18-27
83. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL (2003) Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112(2):275-285
84. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL (2006) Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 50(1):310-317
85. Keil S, Wiedemann B (1995) Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrob Agents Chemother 39(5):1054-1058
86. Khangarot BS, Rathore RS, Tripathi DM (1999) Effects of chromium on humoral and cellmediated immune responses and host resistance to disease in a freshwater catfish, Saccobranchus fossilis (Bloch). Ecotoxicol Environ Saf 43(1):11-20
87. King TC, Schlessinger D, Krogstad DJ (1981) The assessment of antimicrobial combinations. Rev Infect Dis 3(3):627-633
88. Krylov VN (2003) Role of horizontal gene transfer by bacteriophages in the origin of pathogenic bacteria. Genetika 39(5):595-620
89. Kucers A, Bennett NM (1987) Vancomycin. In: Kucers A, Bennett NM, eds. The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 4th ed. Philadelphia, JB Lippinott Co, pp 1045-1068
90. LeClerc JE, Li B, Payne WL, Cebula TA (1996) High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274(5290):1208-1211
91. Lee JJ, Kong M (2009) Confidence intervals of interaction index for assessing multiple drug interaction. Stat Biopharm Res 1(1):4-17
92. Lee JJ, Kong M, Ayers GD, Lotan R (2007) Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 17(3):461-480
93. Liehl B, Hlavaty J, Moldzio R, Tonar Z, Unger H, Salmons B, Gunzburg WH, Renner M (2007) Simian immunodeficiency virus vector pseudotypes differ in transduction efficiency and target cell specificity in brain. Gene Ther 14(18):1330-1343
94. Lipsitch M, Samore MH (2002) Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8(4):347-354
95. Lister PD, Pong A, Chartrand SA, Sanders CC (1997) Rationale behind high-dose amoxicillin therapy for acute otitis media due to penicillin-nonsusceptible pneumococci: support from in vitro pharmacodynamic studies. Antimicrob Agents Chemother 41(9):1926-1932
96. Livermore DM (2002) Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 34(5):634-640
97. Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL (2001) Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 45(3):845-851
98. MacGowan AP, Wootton M, Hedges AJ, Bowker KE, Holt HA, Reeves DS (1996) A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone. J Antimicrob Chemother 38(2):193-203
99. Madaras-Kelly KJ, Ostergaard BE, Hovde LB, Rotschafer JC (1996) Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother 40(3):627-632
100. Mager DE, Wyska E, Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31(5):510-518
101. McKenzie GJ, Harris RS, Lee PL, Rosenberg SM (2000) The SOS response regulates adaptive mutation. Proc Natl Acad Sci U S A 97(12):6646-6651
102. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG (2007) Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 51(6):1939-1945
103. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN (2004) SOS response induction by beta-lactams and bacterial defense against antibiotic lethality. Science 305(5690):1629-1631
104. Montgomery MJ, Beringer PM, Aminimanizani A, Louie SG, Shapiro BJ, Jelliffe R, Gill MA (2001) Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 45(12):3468-3473
105. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, Richardson P, Bruce D, Rubin E, Myers E, Siggia ED, Tomasz A (2007) Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci USA 104(22):9451-9456
106. Neu HC (1992) The crisis in antibiotic resistance. Science 257(5073):1064-1073
107. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ (1995) Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and betalactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother 39(8):1764-1771
108. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18(4):657-686
109. Peck CC, Cross JT (2007) Getting the dose right: facts, a blueprint, and encouragements. Clin Pharmacol Ther 82(1):12-14
110. Peterson LR, Moody JA, Fasching CE, Gerding DN (1989) Influence of protein binding on therapeutic efficacy of cefoperazone. Antimicrob Agents Chemother 33(4):566-568
111. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M (1998) Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279(2):125-129
112. Prichard MN, Prichard LE, Shipman C Jr (1993) Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37(3):540-545
113. Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL (2009) Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrob Agents Chemother 53(8):3294-3301
114. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T (2010) Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 201(8):1225-1231
115. Tam VH, Schilling AN, Nikolaou M (2005) Modelling time-kill studies to discern the pharmacodynamics of meropenem. J Antimicrob Chemother 55(5):699-706
116. Van Der Graaf PH, Danhof M (1997) On the reliability of affinity and efficacy estimates obtained by direct operational model fitting of agonist concentration-effect curves following irreversible receptor inactivation. J Pharmacol Toxicol Methods 38(2):81-85
117. Van der Graaf PH, Schoemaker RC (1999) Analysis of asymmetry of agonist concentration-effect curves. J Pharmacol Toxicol Methods 41(2-3):107-115
118. Wainberg MA, Friedland G (1998) Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279(24):1977-1983
119. Weigel LM, Clewell DB, Gill SR, Clark NC, McDougal LK, Flannagan SE, Kolonay JF, Shetty J, Killgore GE, Tenover FC (2003) Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus. Science 302(5650):1569-1571
120. Whitehead A, Whitehead J, Todd S, Zhou Y, Smith MK (2008) Fitting models for the joint action of two drugs using SAS. Pharm Stat 7(4):272-284
121. Williams JB (1996) Drug efflux as a mechanism of resistance. Br J Biomed Sci 53:290-293
122. Zelenitsky S, Ariano R, Harding G, Forrest A (2005) Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother 49(10):4009-4014
123. Zhang Y, Young D (1994) Molecular genetics of drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 34(3):313-319
124. Zhi J, Nightingale CH, Quintiliani R (1986) A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J Pharm Sci 75(11):1063-1067
125. Zinner SH, Blaser J (1986) In vitro models in the study of antibiotic therapy of infections in neutropenic patients. Am J Med 80(5C):40-44